Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: Dauntless who wrote (617)	4/16/1998 8:49:00 PM
From: gaddis	Read Replies (1) \| Respond to of 834

I've heard people make the case for at least a $400 million market cap for TXB after FDA approval of Novastan. This is based on the market size for the HIT indication as well as the value of their drugs in development. One bonus is that the company can begin to market Novastan very soon after approval. I looked at a list of institutions invested in TXB and was very impressed. If Novastan meets with FDA approval, I have to believe that we'll see some more institutional buying. My impression is that management is intent on having the warrants exercised and bringing in that substantial cash. A big pharma deal(s) would definitely ensure that the stock price stays over $8.44 once the excitement over the approval subsides. I'm confident that they can make it happen.